文章基本信息

标题：Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia
本地全文：下载
作者：Hugo Van Herendael ; Paul Dorian
期刊名称：Vascular Health and Risk Management
印刷版ISSN：1176-6344
电子版ISSN：1178-2048
出版年度：2010
卷号：6
页码：465-472
DOI：10.2147/VHRM.S6611
出版社：Dove Medical Press Ltd
摘要：Amiodarone has emerged as the leading antiarrhythmic therapy for termination and prevention of ventricular arrhythmia in different clinical settings because of its proven efficacy and safety. In patients with shock refractory out-of-hospital cardiac arrest and hemodynamically destabilizing ventricular arrhythmia, amiodarone is the most effective drug available to assist in resuscitation. Although the superiority of the transvenous implantable cardioverter defibrillator (ICD) over amiodarone has been well established in the preventive treatment of patients at high risk of life-threatening ventricular arrhythmias, amiodarone (if used with a beta-blocker) is the most effective antiarrhythmic drug to prevent ICD shocks and treat electrical storm. Both the pharmacokinetics and the electrophysiologic profile of amiodarone are complex, and its optimal and safe use requires careful patient surveillance with respect to potential adverse effects.
关键词：amiodarone; ventricular fibrillation; unstable ventricular tachycardia